STOCK TITAN

Turn Therapeutics (TTRX) 10-K Filings

TTRX NASDAQ

Here are the 10-K annual reports from Turn Therapeutics Inc. (TTRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow TTRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TTRX filings page.

Rhea-AI Summary

Turn Therapeutics Inc. files its annual report describing a dermatology-focused pipeline built around GX-03, a non-systemic topical immunomodulator for moderate-to-severe eczema and onychomycosis, plus an exploratory thermostable intranasal vaccine platform.

The company leverages prior 510(k) device clearances and animal data to run an approximately 114–120 patient randomized, double-blind, vehicle-controlled Phase 2-equivalent eczema trial, with interim analysis at 50% enrollment and topline results expected mid-2026. GX-03 has shown preclinical cytokine inhibition and antifungal nail penetration with favorable tolerability. Turn pursues a capital-light model using contract manufacturers and partners, highlighted by a MiMedx license for the collagen-based FleX Product with up to $69.55 million in potential milestones plus mid-single-digit royalties, and an October 2025 Medline agreement to co-develop and distribute PermaFusion-based wound and personal care products globally.

The report also discloses net losses, an accumulated deficit, and substantial doubt about the company’s ability to continue as a going concern, alongside reliance on external financing, including an up to $85.0 million share purchase facility with GEM and potential future equity dilution.